Dan Levy, MD Archives

2023 FUTURES: Friday Keynote – On the Cutting Edge of Research

The science and research-focused day of FUTURES will begin with an engaging keynote panel featuring key opinion leaders who will discuss the successes, learnings, challenges, and future of this disease space.

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Dan Levy, MD

VP and Development Head, Rare Neurology Pfizer

See more from same speaker

Carsten Bönnemann, MD

Chief, Neuromuscular and Neurogenetic Disorders of Childhood Section National Institute of Neurological Disorders and Stroke/NIH

See more from same speaker

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

See more from same speaker

2023 FUTURES: Gene Therapy and Gene Editing Sessions

A brief primer on the gene therapy and gene editing approach to treating Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Jahannaz Dastgir, DO

Clinical Development Lead REGENXBIO

See more from same speaker

Patrick Gonzalez, PhD

Senior Director of Clinical Science Solid Biosciences

See more from same speaker

Teji Singh, MD

Vice President, Head of Clinical Development Sarepta Therapeutics

See more from same speaker

Dan Levy, MD

VP and Development Head, Rare Neurology Pfizer

See more from same speaker

Dan Levy, MD

Michael Kelly, PhD

Emil Kakkis, PhD

Alison Mcvie-Wylie, PhD

Dan Levy, MD

Carsten Bönnemann, MD

Kevin Flanigan, MD

Share this:

Alison Mcvie-Wylie, PhD

Jahannaz Dastgir, DO

Patrick Gonzalez, PhD

Teji Singh, MD

Dan Levy, MD

Share this: